Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Biological: BAX69 + infusional 5-FU/LV
Biological: BAX69 + panitumumab
Biological: Standard of Care
Biological: BAX69 + 5-FU/LV

Registration Number: NCT02448810

Lead Sponsor: Baxalta now part of Shire

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 115

Inclusion Criteria

Provision of a signed informed consent
Male and female subjects 18 years of age and older at the time of screening
Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines
Anticipated life expectancy >3 months at the time of screening
Weight between 40 kg and 180 kg
Histologically or cytologically confirmed diagnosis of CRC
Metastatic CRC not amenable to surgical resection
Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)
At least 1 measurable lesion as defined by RECIST v1.1
ECOG PS of 0-2
Adequate hematological function, defined as:
1. Platelet count ≥ 100,000/μL
2. Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
3. Absolute neutrophil count (ANC) ≥ 1,000/μL
4. Hemoglobin ≥ 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/min
Adequate liver function, defined as:
1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
  
  ≤ 2.5 times ULN for subjects without liver metastases, or ≤ 5 times ULN in the presence of liver metastases
2. Bilirubin ≤ 2.0 times ULN, unless subject has known Gilbert's syndrome
Adequate venous access
For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69
Subject is willing and able to comply with the requirements of the protocol.

Exclusion Criteria

Known central nervous system metastases
Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor
Residual AE from previous treatment > Grade 1
Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirmed upon repeated measures
LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1
QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1
Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.
Major surgery within 4 weeks prior to C1D1
Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
Active infection involving IV antibiotics within 2 weeks prior to C1D1
Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
Subject has received a live vaccine within 4 weeks prior to C1D1
Known hypersensitivity to any component of recombinant protein production by CHO cells
Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
Subject is nursing or intends to begin nursing during the course of the study
Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study
Subject is a family member or employee of the investigator

Study & Design

Study Type: INTERVENTIONAL

Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)	BAX69 + infusional 5-FU/LV	Subjects stratified according to their mutation status.
Part 2: Subjects with KRAS and NRAS wt tumor	BAX69 + panitumumab	Subjects stratified according to their mutation status.
Part 2: Standard of Care- Subjects with KRAS or NRAS mutated	Standard of Care	Subjects stratified according to their mutation status.
Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)	BAX69 + panitumumab	Subjects stratified according to their mutation status.
Part 2: Subjects with KRAS or NRAS mutated	BAX69 + 5-FU/LV	Subjects stratified according to their mutation status.
Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor	Standard of Care	Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.

Primary Outcome Measures

Name	Time	Method
Part 2: Progression-Free Survival (PFS)	From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression	PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.
Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT)	From start of study treatment up to 28 days	DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any \>= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of \<3 days duration; nausea and vomiting \<3 days duration; fatigue of \<7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to \<= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for \<= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)	From start of study drug administration up to EOT (approximately 21 Months)	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any AE that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of an existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, other medically important events based upon appropriate medical judgement. TEAEs was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.
Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies	From start of study drug administration up to end of treatment (EOT) (approximately 21 Months)	Number of participants with occurrence of binding and/or neutralizing anti-imalumab antibodies were reported.
Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224	Number of participants with response evaluation according to RECIST v1.1 was evaluated according to complete response (CR): disappearance of all target and non-target lesions and no new lesions; partial response (PR): \>= 30 percent (%) decrease in the sum of diameters of target lesions (compared to baseline) and no new lesions; stable disease (SD): neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; progressive disease (PD): \>= 20% increase in the sum of diameters of target lesions and an absolute increase in sum of diameters of \>=5 millimeter (mm) (compared to the previous minimum sum) or progression of a new lesion.
Overall Survival	From start of study drug administration up to EOT (approximately 21 Months)	Overall survival was defined as the time from randomization until death due to any cause. Here, number of participants analyzed was based on the number of participants who underwent death.
Number of Participants With Incidence of Infusion Reactions After Imalumab Administration	From start of study drug administration up to EOT (approximately 21 Months)	Infusion reaction was defined as any relevant sign or symptom occurring during or after imalumab infusion and considered by the investigator as an infusion reaction.
Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	Baseline, 21 Months (EOT) up to follow-up	EORTC QLQ-C30 was a validated instrument used to measure QoL and assess symptoms and side effects of treatment and the impact on everyday life.The QLQ-C30 was composed of: A) 5 multi-item functioning scales(physical, role, social, emotional and cognitive), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a higher level of functioning and a better QoL. B) A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score range from 0 to 100 with a higher score representing a better QoL. C) 9 symptom scales(fatigue, nausea/vomiting,pain,financial impact/difficulties,appetite loss,diarrhea, constipation,sleep disturbance/insomnia and dyspnea), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a greater degree of symptoms and a worse QoL.

Trial Locations

Locations (12): CTRC at University of Texas Health Science Center
🇺🇸
San Antonio, Texas, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Montefiore Einstein Center for Cancer Care
🇺🇸
Bronx, New York, United States
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Hematology Oncology Associates of the Treasure Coast
🇺🇸
Port Saint Lucie, Florida, United States
Joliet Oncology-Hematology Associates, Ltd.
🇺🇸
Joliet, Illinois, United States
Mount Sinai Beth Israel
🇺🇸
New York, New York, United States
Maryland Oncology Hematology, P.A.
🇺🇸
Rockville, Maryland, United States
Indiana University Health
🇺🇸
Goshen, Indiana, United States
Mary Crowley Cancer Research Center
🇺🇸
Dallas, Texas, United States
Medical University of South Carolina (MUSC)
🇺🇸
Charleston, South Carolina, United States
The Jones Clinic, PC
🇺🇸
Germantown, Tennessee, United States